Larotrectinib efficacy and price

Larotrectinib is a targeted anticancer drug whose main function is to inhibit the activity of abnormal TRK protein in cancer patients with TRK (neuroectodermal tumor) gene fusion. The following are the main effects of larotrectinib:

1.TargetedTRKgene fusion: Larotrectinib is unique in its targeting and is mainly used in patients with tumors suffering from TRKgene fusion. The TRK gene encodes the nerve growth factor receptor in normal cells, but in the fusion state it may lead to abnormal TRK protein, thereby promoting the growth and differentiation of cancer cells.

2.Personalized treatment: Larotinib represents a model of personalized medicine. By conducting genetic testing to determine whether a patient has a TRK gene fusion, it can be more accurately determined whether the patient is suitable for larotrectinib treatment. This personalized treatment approach can help improve the targeting of treatment and reduce unnecessary treatment exposure.

3.Causing tumor shrinkage or stabilization: Clinical trial results show that for patients with TRK gene fusion positive, the use of larotrectinib can cause tumor shrinkage or stabilization. This has a positive impact on improving patient survival and quality of life.

4.Durable therapeutic effects: In some studies, patients using larotrectinib have shown sustained therapeutic effects. This makes larotrectinib a long-term treatment option for some cancer patients, bringing new hope to those who previously lacked effective treatment options.

5.Relatively good safety and tolerability: Larotinib has shown relatively good safety and tolerability in clinical trials. Patients generally respond well to this treatment, and common side effects are usually mild, such as fatigue, headache, and vomiting.

Overall, the efficacy of larotrectinib is to provide a personalized, targeted treatment option for cancer patients with TRK gene fusion-positive cancers. By blocking the activity of abnormal TRK proteins, larotrectinib is expected to bring significant therapeutic effects and improve patients' survival and quality of life. Before using larotrectinib, patients should undergo genetic testing under the guidance of a doctor and fully understand the possible effects and potential side effects of treatment.

Larotrectinib has been launched in China and has not yet been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in hospitals. For specific conditions, it is recommended to consult the local hospital pharmacy. In foreign markets, larotinib has two options: original drug and generic drug. Original drugs include the German version, the American version, the European version and the Hong Kong version, and the price is about 10,000 to 20,000 yuan. In comparison, generic drugs are much cheaper. There are Lao and Bangladeshi versions of generic drugs, and the price is around two to three thousand. It is worth noting that the ingredients of original drugs and generic drugs are basically the same.